Large gap with delayed quotes
|
Last quote
07/03/2025
-
23:00:00
|
Bid
07/03/2025 -
18:59:59
|
Bid Volume |
Ask
07/03/2025 -
18:59:59
|
Ask Volume |
|---|---|---|---|---|
|
52.17
+0.50
(
+0.97% )
|
52.11
|
400 |
52.12
|
3,100 |
Analysis date: 01.07.2025
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 06.06.2025.
Interest
Strong
Strong
Three stars since 06.06.2025.
Earnings Rev Trend
0.10
0.10
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is positive since 25.04.2025 at a price of 38.27.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Positive
Positive
The forty day technical trend is positive since 06.06.2025.
4wk Rel Perf
26.87%
26.87%
The four-week dividend-adjusted overperformance versus SP500 is 26.87%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 1.91%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.42%.
Mkt Cap in $bn
4.20
4.20
With a market capitalization between $2 & $8bn, CRISPR THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
-0.31
-0.31
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
-13.40
-13.40
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
-4.15%
-4.15%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
22
22
Over the last seven weeks, an average of 22 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
157
157
For 1% of index variation, the stock varies on average by 1.57%.
Correlation
0.52
0.52
52.30% of stock movements are explained by index variations.
Value at Risk
31.12
31.12
The value at risk is estimated at USD 31.12. The risk is therefore 64.15%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
08.09.2020
08.09.2020